alendronate has been researched along with ono-5334 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boonen, S; Deacon, S; Eastell, R; Kuwayama, T; Nagase, S; Ohyama, M; Small, M; Spector, T | 1 |
| Imagawa, A; Kawabata, K; Kawada, N; Kayasuga, R; Mori, H; Nakanishi, Y; Ochi, Y; Ohmoto, K; Tanaka, M; Yamada, H | 1 |
| Deacon, S; Hashimoto, Y; Kuwayama, T; Manako, J; Nagase, S; Ohyama, M; Sharpe, J; Small, M | 1 |
2 trial(s) available for alendronate and ono-5334
| Article | Year |
|---|---|
Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal; Thiazolidines; Time Factors | 2014 |
Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women.
Topics: Aged; Alendronate; Area Under Curve; Bone and Bones; Bone Density; Bone Resorption; Cathepsin K; Collagen Type I; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Single-Blind Method; Thiazolidines | 2015 |
1 other study(ies) available for alendronate and ono-5334
| Article | Year |
|---|---|
ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Cathepsin K; Female; Osteoporosis; Ovariectomy; Rats; Thiazolidines; Tibia | 2014 |